PIAS
CRSP icon

PCA Investment Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

PCA Investment Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$5.61K – 170
2023
Q2 		$5.61K Buy
+100
New +$5.67K ﹤0.01% 423

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCA Investment Advisory Services's CRSP Position: Q3 2023 in Review

PCA Investment Advisory Services sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 100 shares — an estimated $5.61K sold.

PCA Investment Advisory Services first reported a position in CRSP in Q2 2023 and held it in 1 quarter. The position peaked at $5.61K in Q2 2023. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • PCA Investment Advisory Services reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • PCA Investment Advisory Services sold 100 CRISPR Therapeutics shares in Q3 2023, an estimated $5.61K.
  • PCA Investment Advisory Services first reported a position in CRISPR Therapeutics in Q2 2023 and held it in 1 quarter.
  • PCA Investment Advisory Services's CRISPR Therapeutics position peaked at $5.61K in Q2 2023.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on PCA Investment Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.